MA43800A - Octréotide par voie orale pour le traitement de maladies - Google Patents

Octréotide par voie orale pour le traitement de maladies

Info

Publication number
MA43800A
MA43800A MA043800A MA43800A MA43800A MA 43800 A MA43800 A MA 43800A MA 043800 A MA043800 A MA 043800A MA 43800 A MA43800 A MA 43800A MA 43800 A MA43800 A MA 43800A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
oral octreotide
octreotide
oral
Prior art date
Application number
MA043800A
Other languages
English (en)
Inventor
Dana Gelbaum
Asi Haviv
Roni Mamluk
Gary Patou
Original Assignee
Chiasma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiasma Inc filed Critical Chiasma Inc
Publication of MA43800A publication Critical patent/MA43800A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043800A 2016-01-21 2017-01-20 Octréotide par voie orale pour le traitement de maladies MA43800A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281320P 2016-01-21 2016-01-21
US201662299607P 2016-02-25 2016-02-25
US201662303072P 2016-03-03 2016-03-03

Publications (1)

Publication Number Publication Date
MA43800A true MA43800A (fr) 2021-05-12

Family

ID=59362439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043800A MA43800A (fr) 2016-01-21 2017-01-20 Octréotide par voie orale pour le traitement de maladies

Country Status (7)

Country Link
US (4) US20210187079A1 (fr)
EP (1) EP3405211A4 (fr)
AU (2) AU2017210227A1 (fr)
CA (2) CA3290933A1 (fr)
IL (1) IL311974A (fr)
MA (1) MA43800A (fr)
WO (1) WO2017127710A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
WO2018222921A1 (fr) 2017-05-31 2018-12-06 Napo Pharmaceuticals, Inc. Procédés et compositions pour le traitement de la diarrhée causée par les acides biliaires, de la diarrhée associée à une résection de l'intestin grêle ou à l'ablation de la vésicule biliaire, et du syndrome de l'intestin court
CN111068041A (zh) * 2020-01-19 2020-04-28 中国药科大学 奥曲肽在制备治疗溃疡性结肠炎药物中的应用
US20210353624A1 (en) * 2020-05-13 2021-11-18 Tersera Therapeutics Llc Method of treating cancer with telotrisat or a prodrug thereof
US20220202911A1 (en) * 2020-12-28 2022-06-30 Amryt Endo, Inc. Oral octreotide therapy in combination with digoxin or lisinopril
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
EP4482491A4 (fr) * 2022-02-25 2026-02-25 Amryt Endo Inc Octréotide oral pour traitement d'une maladie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
US6159935A (en) * 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
WO2006127214A1 (fr) * 2005-05-23 2006-11-30 Mayo Foundation For Medical Education And Research Traitement de maladies du foie
EP2275103B1 (fr) * 2005-11-21 2014-04-23 Novartis AG Inhibiteurs du mTOR pour le traitement des tumeurs endocriniennes
ES3058497T3 (en) * 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
WO2011112576A1 (fr) * 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microsphères pour une libération entretenue d'acétate d'octréotide
TWI633887B (zh) * 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
BR112014030777A2 (pt) * 2012-06-21 2017-06-27 Angiogene Pharm Ltd método e composição para aliviar sintomas de tumor
WO2014049515A1 (fr) * 2012-09-25 2014-04-03 Piramal Enterprises Limited Flavones à substitution pyrrolidine pour le traitement de maladies kystiques rénales
US20150283147A1 (en) * 2012-10-19 2015-10-08 Synta Pharmaceuticals Corp. Treating polycystic kidney disease with hsp90 inhibitory compounds

Also Published As

Publication number Publication date
NZ744515A (en) 2025-08-29
US20230173034A1 (en) 2023-06-08
US20210187079A1 (en) 2021-06-24
CA3011982A1 (fr) 2017-07-27
IL311974A (en) 2024-06-01
EP3405211A1 (fr) 2018-11-28
AU2024201385A1 (en) 2024-03-21
EP3405211A4 (fr) 2019-10-09
US20240016899A1 (en) 2024-01-18
CA3290933A1 (en) 2025-11-29
AU2017210227A1 (en) 2018-09-06
WO2017127710A1 (fr) 2017-07-27
US20250339499A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3405211A4 (fr) Octréotide par voie orale pour le traitement de maladies
MA45192A (fr) Traitement d'association
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
EP3716767A4 (fr) Méthodes et compositions pour le traitement de maladies rares
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
ME03314B (fr) Thérapie basée sur l'arnm pour le traitement des maladies oculaires
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
MA41449A (fr) Polythérapies pour le traitement de cancers
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3454896A4 (fr) Dérivés hétérocycliques pour le traitement de rsv
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
EP3634463A4 (fr) Protocole amélioré pour le traitement de la néphropathie lupique